Anthony P Y Liu1, Camden Hastings2, Shengjie Wu3, Johnnie K Bass4, Andrew M Heitzer5, Jason Ashford5, Robert Vestal6, Mary E Hoehn6,7, Yahya Ghazwani1, Sahaja Acharya8, Heather M Conklin5, Frederick Boop7,9,10,11, Thomas E Merchant8, Amar Gajjar1, Ibrahim Qaddoumi1. 1. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Pediatric Oncology Education Program, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. St. Jude Children's Research Hospital, Rehabilitation Services, Memphis, Tennessee. 5. Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee. 7. Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee. 8. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 9. Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, Tennessee. 10. Le Bonheur Neuroscience Institute, Le Bonheur Children's Hospital, Memphis, Tennessee. 11. Semmes Murphey Clinic, Memphis, Tennessee.
Abstract
BACKGROUND: Low-grade gliomas (LGGs) and low-grade glioneuronal tumors (LGGNTs) diagnosed during the first year of life carry unique clinical characteristics and challenges in management. However, data on the treatment burden, outcomes, and morbidities are lacking. METHODS: A retrospective study of LGGs and LGGNTs diagnosed in patients younger than 12 months at St. Jude Children's Research Hospital (1986-2015) was conducted. RESULTS: For the 51 patients (including 31 males), the mean age at diagnosis was 6.47 months (range, 0.17-11.76 months), and the mean follow-up period was 11.8 years (range, 0.21-29.19 years). Tumor locations were hypothalamic/optic pathway (61%), hemispheric (12%), brainstem (12%), cerebellar (8%), and spinal (8%). There were 41 patients with histological diagnoses: 28 had World Health Organization grade 1 tumors, 6 had grade 2 tumors, and 7 had an LGG/LGGNT not definitively graded. Forty-one patients required an active intervention at diagnosis. Throughout their treatment course, 41 patients eventually underwent tumor-directed surgeries (median, 2 surgeries; range, 1-6), 39 received chemotherapy (median, 2 regimens; range, 1-13), and 21 received radiotherapy. Forty patients experienced disease progression (median, 2 progressions; range, 1-18). Ten patients died of progression (n = 5), malignant transformation (n = 2), a second cancer (n = 2), or a shunt infection (n = 1). The 10-year overall survival, progression-free survival, and radiation-free survival rates were 85% ± 5.3%, 16.9% ± 5.3%, and 51.2% ± 7.5%, respectively. Forty-nine patients experienced health deficits (eg, endocrinopathies, obesity, seizures, visual/hearing impairments, neurocognitive impairments, and cerebrovascular disease). Predictors of progression and toxicities were defined. CONCLUSIONS: Infantile LGG/LGGNT is a chronic, progressive disease universally associated with long-term morbidities and requires multidisciplinary intervention.
BACKGROUND: Low-grade gliomas (LGGs) and low-grade glioneuronal tumors (LGGNTs) diagnosed during the first year of life carry unique clinical characteristics and challenges in management. However, data on the treatment burden, outcomes, and morbidities are lacking. METHODS: A retrospective study of LGGs and LGGNTs diagnosed in patients younger than 12 months at St. Jude Children's Research Hospital (1986-2015) was conducted. RESULTS: For the 51 patients (including 31 males), the mean age at diagnosis was 6.47 months (range, 0.17-11.76 months), and the mean follow-up period was 11.8 years (range, 0.21-29.19 years). Tumor locations were hypothalamic/optic pathway (61%), hemispheric (12%), brainstem (12%), cerebellar (8%), and spinal (8%). There were 41 patients with histological diagnoses: 28 had World Health Organization grade 1 tumors, 6 had grade 2 tumors, and 7 had an LGG/LGGNT not definitively graded. Forty-one patients required an active intervention at diagnosis. Throughout their treatment course, 41 patients eventually underwent tumor-directed surgeries (median, 2 surgeries; range, 1-6), 39 received chemotherapy (median, 2 regimens; range, 1-13), and 21 received radiotherapy. Forty patients experienced disease progression (median, 2 progressions; range, 1-18). Ten patientsdied of progression (n = 5), malignant transformation (n = 2), a second cancer (n = 2), or a shunt infection (n = 1). The 10-year overall survival, progression-free survival, and radiation-free survival rates were 85% ± 5.3%, 16.9% ± 5.3%, and 51.2% ± 7.5%, respectively. Forty-nine patients experienced health deficits (eg, endocrinopathies, obesity, seizures, visual/hearing impairments, neurocognitive impairments, and cerebrovascular disease). Predictors of progression and toxicities were defined. CONCLUSIONS: Infantile LGG/LGGNT is a chronic, progressive disease universally associated with long-term morbidities and requires multidisciplinary intervention.
Authors: Raymond K Mulhern; Shawna L Palmer; Thomas E Merchant; Dana Wallace; Mehmet Kocak; Pim Brouwers; Kevin Krull; Murali Chintagumpala; Robyn Stargatt; David M Ashley; Vida L Tyc; Larry Kun; James Boyett; Amar Gajjar Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Sundeep R Bhat; Tress L Goodwin; Tasha M Burwinkle; Meagan F Lansdale; Gary V Dahl; Stephen L Huhn; Iris C Gibbs; Sarah S Donaldson; Ruth K Rosenblum; James W Varni; Paul G Fisher Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Martin Benesch; Herwig Lackner; Petra Sovinz; Elisabeth Suppan; Wolfgang Schwinger; Hans-Georg Eder; Hans Jürgen Dornbusch; Andrea Moser; Karin Triebl-Roth; Christian Urban Journal: J Neurooncol Date: 2006-04-25 Impact factor: 4.130
Authors: Richard M Awdeh; Erin N Kiehna; Richard D Drewry; Natalie C Kerr; Barrett G Haik; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-18 Impact factor: 7.038
Authors: Dean W Beebe; M Douglas Ris; F Daniel Armstrong; John Fontanesi; Raymond Mulhern; Emi Holmes; Jeffrey H Wisoff Journal: J Clin Oncol Date: 2005-08-01 Impact factor: 44.544
Authors: Roberto Rivera-Luna; Aurora Medina-Sanson; Carlos Leal-Leal; Francisco Pantoja-Guillen; Marta Zapata-Tarrés; Rocio Cardenas-Cardos; Rafael Barrera-Gómez; Fernando Rueda-Franco Journal: Childs Nerv Syst Date: 2003-05-06 Impact factor: 1.475